[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]

Year

Day

May 30, 2017
Viewpoint

Evolving State-Based Contraceptive and Abortion Policies

Abstract Full Text
free access
JAMA. Published online May 30, 2017. doi:10.1001/jama.2017.6103

This Viewpoint discusses the importance of US state-based contraceptive and abortion policies given renewed focus by the Trump administration on restrictions to federal funding for reproductive services.

May 25, 2017
Viewpoint

Direct-to-Consumer Medical Testing in the Era of Value-Based Care

Abstract Full Text
free access
JAMA. Published online May 25, 2017. doi:10.1001/jama.2017.5929

This Viewpoint documents the growing market share of direct-to-consumer (DTC) medical testing despite growing recognition that it represents low-value or harmful care and proposes policy options to increase accountability and protect patients from adverse consequences of DTC testing.

May 18, 2017
Viewpoint

Pharmaceutical Marketing for Rare DiseasesRegulating Drug Company Promotion in an Era of Unprecedented Advertisement

Abstract Full Text
free access
JAMA. Published online May 18, 2017. doi:10.1001/jama.2017.5784

This Viewpoint uses the recent instance of disease awareness promotion on a television soap opera to discuss questions about the role and regulation of novel forms of direct-to-consumer disease awareness marketing.

May 15, 2017
Viewpoint

Financing and Distribution of Pharmaceuticals in the United States

Abstract Full Text
free access
JAMA. Published online May 15, 2017. doi:10.1001/jama.2017.5607

This Viewpoint identifies stakeholders in the financing and distribution of pharmaceuticals in the United States and describes their flow from manufacturers through distributors, managers, and retailers to patients.

May 1, 2017
Viewpoint

Defending Biomedical Science in an Era of Threatened Funding

Abstract Full Text
free access
JAMA. Published online May 1, 2017. doi:10.1001/jama.2017.5811

In this Viewpoint, John Ioannidis discusses how the medical community, other scientists, and the public can defend science under the mounting pressure of threatened funding.

×